Frederik Paulsen is stepping down from his role as Ferring’s chairman of the board of directors after 33 years, the company has announced.
The Swedish billionaire, who has been in the job since 1988, has overseen an expansion of Ferring’s presence into almost 60 countries and an increase in its annual revenues to nearly two billion euros ($2.4 billion). He is now transitioning to the role of honorary chairman and will dedicate more time to his passions of polar exploration and climate change science, as well as his philanthropic activities and various investments.
Lars Rebien Sørensen, who was president and chief executive of Danish diabetes giant Novo Nordisk (NOV: N) from 2000 until 2016, is taking over as chairman of the board at Ferring, which is now based in Switzerland.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze